Histocyte Laboratories

Executive Summary

Histocyte Laboratories is a UK-based company, founded in 2015, that specializes in producing formalin-fixed, paraffin-embedded (FFPE) cell line-based quality control materials for immunohistochemistry (IHC) and in situ hybridization (ISH). These standardized controls address critical challenges in histopathology, such as biomarker heterogeneity and tissue scarcity, enabling reproducible and reliable diagnostic testing. By providing easy-to-integrate controls for routine workflows, Histocyte supports accurate biomarker assessment and consistent results across laboratories, which is essential for personalized medicine and companion diagnostics. With the growing adoption of IHC and ISH in cancer diagnosis and treatment selection, the demand for high-quality controls is increasing. Histocyte’s products have the potential to become industry standards, reducing variability and improving patient outcomes. The company is poised for growth by expanding into new markets, particularly the US, and by developing controls for emerging biomarkers like PD-L1. Its strong niche in diagnostic quality assurance positions it as a key enabler for precision oncology.

Upcoming Catalysts (preview)

• 2026-2027Expansion into US market60% success
• Q4 2026Launch of comprehensive IHC control panel for PD-L1 testing70% success
• 2027Strategic partnership with major diagnostic laboratory50% success